Abstract
Considerable evidence has been provided these last years for the involvement of the GABA-A receptor complex in memory processes. Compounds that enhance the action of GABA, such as benzodiazepines, impair memory processing. On the contrary, compounds that reduce the action of GABA, such as ß-CCM, pentylenetetrazol or picrotoxin, have the opposite action, that is : enhance memory processing. All these actions seem to focus mainly on the acquisition (learning) processes. Depending on the dose, the same compounds also have effects on anxiety and on seizuring. Benzodiazepines are well-known anxiolytic and anticonvulsant agents whereas compounds that reduce the action of GABA have been found to produce anxiogenic and convulsant actions. The GABA-A receptor complex might thus be the location of a possible link between a pathological state (epilepsy) and two normal functions (anxiety and learning). This link is likely to involve common genetic pathways. In the normal subject, these data also emphasize the idea that normal memory processing involves a moderate level of anxiety.
Keywords: gaba receptor complex, pentylenetetrazol, picrotoxin, learning, anxiety, epilepsy
Current Topics in Medicinal Chemistry
Title: GABA-A Receptor Complex and Memory Processes
Volume: 2 Issue: 8
Author(s): Georges Chapouthier and Patrice Venault
Affiliation:
Keywords: gaba receptor complex, pentylenetetrazol, picrotoxin, learning, anxiety, epilepsy
Abstract: Considerable evidence has been provided these last years for the involvement of the GABA-A receptor complex in memory processes. Compounds that enhance the action of GABA, such as benzodiazepines, impair memory processing. On the contrary, compounds that reduce the action of GABA, such as ß-CCM, pentylenetetrazol or picrotoxin, have the opposite action, that is : enhance memory processing. All these actions seem to focus mainly on the acquisition (learning) processes. Depending on the dose, the same compounds also have effects on anxiety and on seizuring. Benzodiazepines are well-known anxiolytic and anticonvulsant agents whereas compounds that reduce the action of GABA have been found to produce anxiogenic and convulsant actions. The GABA-A receptor complex might thus be the location of a possible link between a pathological state (epilepsy) and two normal functions (anxiety and learning). This link is likely to involve common genetic pathways. In the normal subject, these data also emphasize the idea that normal memory processing involves a moderate level of anxiety.
Export Options
About this article
Cite this article as:
Chapouthier Georges and Venault Patrice, GABA-A Receptor Complex and Memory Processes, Current Topics in Medicinal Chemistry 2002; 2 (8) . https://dx.doi.org/10.2174/1568026023393552
DOI https://dx.doi.org/10.2174/1568026023393552 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials
Current Pharmaceutical Design Editorial Review 2015
Current Radiopharmaceuticals HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities
Current HIV Research Therapeutic Indications and Action Mechanisms of Bilirubin: Suggestions from Natural Calculus Bovis
Current Signal Transduction Therapy Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Genetic and Environmental Factors in Complex Neurodevelopmental Disorders
Current Genomics Editorial [Hot Topic: Glutamate Receptors and Related Processes as Drug Targets (Guest Editor: Michel Baudry)]
Current Drug Targets Development and Validation of 'Level A' In Vitro - In Vivo Correlation for Extended Release Tablets of Lamotrigine
Current Bioactive Compounds Omega-3 Fatty Acids and their Role in Central Nervous System - A Review
Current Medicinal Chemistry Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease
Current Pharmaceutical Design Multivariate Analysis of Magnetic Resonance Imaging Signals of the Human Brain
Current Topics in Medicinal Chemistry Safety of Inhaled Corticosteroids. Why the Variation in Systemic Adverse Effects?
Current Pediatric Reviews New Adamantane Derivatives with Sigma Affinity and Antiproliferative Activity
Medicinal Chemistry Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Volumetric Analysis of the Hypothalamus, Amygdala and Hippocampus in Non-Suicidal and Suicidal Mood Disorder Patients – A Post-Mortem Study
CNS & Neurological Disorders - Drug Targets Flavonoids as Natural Inhibitors of Jack Bean Urease Enzyme
Letters in Drug Design & Discovery Neuroactive Steroids as Endogenous Modulators of Anxiety
Current Pharmaceutical Design Histamine H<sub>4</sub> Receptor Antagonists: A New Approach for Tinnitus Treatment?
Recent Patents on CNS Drug Discovery (Discontinued)